Mixture of higher primary aliphatic alcohols, its obtention from sugar cane wax and its pharmaceutical uses

A pharmaceutical formulation comprising 0.5-15.0% weight of a mixture of alcohols constituted by the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• and further comprising as pharmaceutical excipients, appropriate fillers, agglutinants, disintegrators, and lubricants.

A pharmaceutical formulation comprising the mixture of higher primary aliphatic alcohols constituted by the following quantitative compositions:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• in combination with acetyl salicylic acid in a quantitative ratio from 20:1 to 1:20, and pharmaceutically acceptable excipients selected from the group consisting of lactose, corn starch, saccharose, magnesium stearate, microcrystalline cellulose, sodium croscarmelose gelatin, cellulose acetophthalate, titanium dioxide, talc, and polyethylene.

A pharmaceutical formulation comprising a mixture of higher primary aliphatic alcohols constituted by the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.8 +/- 0.1% 1-hexacosanol 6.7 +/- 0.3% 1-heptacosanol 3.0 +/- 0.3% 1-octacosanol 65.6 +/- 3.4% 1-nonacosanol 0.7 +/- 0.1% 1-triacontanol 12.5 +/- 0.6% 1-dotriacontanol 5.0 +/- 0.4% 1-tetratriacontanol 0.8 +/- 0.1% ______________________________________
• further comprising acetyl salicylic acid in a quantitative ratio from 20:1 to 1:20, and pharmaceutically acceptable excipients selected from the group consisting of lactose, corn starch, saccharose, magnesium stearate, microcrystalline cellulose, sodium croscarmelose gelatin, cellulose acetophthalate, titanium dioxide, talc, and polyethylene.

A method of using a mixture of higher primary aliphatic alcohols with the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• further comprising excipients selected from the group consisting of agglutinants, disintegrators, lubricants, sliders or fillers as antiplatelet agent.

A method of using a mixture of higher primary aliphatic alcohols with the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• further comprising excipients selected from the group consisting of agglutinants, disintegrators, lubricants, sliders or fillers as antithrombotic agent.

A method of using a mixture of higher primary aliphatic alcohols with the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• further comprising excipients selected from the group consisting of agglutinants, disintegrators, lubricants, sliders or fillers as anti-ischemic agent.

A method of using a mixture of higher primary aliphatic alcohols with the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• further comprising excipients selected from the group consisting of agglutinants, disintegrators, lubricants, sliders or fillers as protective and/or curative agent against gastric ulcer induced by drugs.

A method of using a mixture of higher primary aliphatic alcohols with the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.5-1.0% 1-hexacosanol 5.5-8.5% 1-heptacosanol 2.0-3.5% 1-octacosanol 60.0-70.0% 1-nonacosanol 0.4-1.2% 1-triacontanol 10.0-15.0% 1-dotriacontanol 4.0-6.0% 1-tetratriacontanol 0.4-2.0% ______________________________________
• together with acetyl salicylic acid and further comprising excipients selected from the group consisting of agglutinants, disintegrators, lubricants, sliders or fillers as an antiplatelet, anti-ischemic or antithrombotic agent.

A method of using a mixture of higher primary aliphatic alcohols with the following quantitative composition:

• ______________________________________ 1-tetracosanol 0.8 +/- 0.1% 1-hexacosanol 6.7 +/- 0.3% 1-heptacosanol 3.0 +/- 0.3% 1-octacosanol 65.6 +/- 3.4% 1-nonacosanol 0.7 +/- 0.1% 1-triacontanol 12.5 +/- 0.6% 1-dotriacontanol 5.0 +/- 0.4% 1-tetratriacontanol 0.8 +/- 0.1% ______________________________________
• together with acetyl salicylic acid and further comprising excipients selected from the group consisting of agglutinants, disintegrators, lubricants, sliders or fillers as antiplatelet, anti-ischemic or antithrombotic agent.